Advertisement

Association of Opioid Overdose Risk Factors and Naloxone Prescribing in US Adults

  • Lewei (Allison) LinEmail author
  • Chad M. Brummett
  • Jennifer F. Waljee
  • Michael J. Englesbe
  • Vidhya Gunaseelan
  • Amy S. B. Bohnert
Original Research

Abstract

Background

Prescribing naloxone to patients is a key strategy to prevent opioid overdoses, but little is known about the reach of naloxone prescribing.

Objective

Determine patient factors associated with receiving naloxone and trends over time in patients with key overdose risk factors.

Design

Retrospective observational study.

Participants

Using the Clinformatics DataMart, a US-wide health insurance claims dataset, we compared adults who received opioids and naloxone (opioid+naloxone) from January 2014 to June 2017 with adults who received opioids without naloxone (opioids only), matched on gender, age ± 5 years, month/year of opioid fill, and number of opioid claims.

Main Measures

Key patient-level opioid overdose risk factors included receipt of high-dosage opioids, concurrent benzodiazepines, history of opioid and other substance use disorders, and history of opioid overdose.

Results

We included 3963 opioid+naloxone and 19,815 opioid only patients. Key factors associated with naloxone fills included high opioid daily dosage (50 to < 90 morphine milligram equivalents (MME): AOR = 2.43, 95% CI 2.15–2.76 and ≥ 90 MME: AOR = 3.94, 95% CI 3.47–4.46; reference: < 50 MME), receiving concurrent benzodiazepines (AOR = 1.27, 95% CI 1.16–1.38), and having a diagnosis of opioid use disorder (AOR = 1.56, 95% CI 1.40–1.73). History of opioid overdose was not associated with naloxone (AOR = 0.92, 95% CI 0.74–1.15). The percent of patients receiving naloxone increased, yet less than 2% of patients in any of the key overdose risk factor groups received naloxone by the last 6 months of the study period.

Conclusions

Naloxone prescribing has increased and was more likely to be co-prescribed to patients with some risk factors for overdose. However, overall prescribing remains minimal. Additional efforts are needed across health systems to increase naloxone prescribing for patients at risk for opioid overdose.

KEY WORDS

: overdose prevention naloxone opioids opioid use disorder 

Notes

Funding Information

This work was supported by Precision Health at the University of Michigan, National Institute on Drug Abuse (grant R01 DA042859), and Substance Abuse and Mental Health Services Administration and Michigan Department of Health and Human Services. Dr. Lin was supported in part by a Career Development Award (CDA 18-008) from the US Department of Veterans Affairs Health Services Research & Development Service.

Compliance with Ethical Standards

Conflict of Interest

Dr. Brummett reported holding a patent for peripheral perineural dexmedetomidine licensed to the University of Michigan, being a consultant for Recro Pharma and Heron Therapeutics, and receiving research funding from Neuros Medical. All remaining authors declare that they do not have a conflict of interest.

Disclaimer

The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; or preparation, review, and approval of the manuscript and decision to submit the manuscript for publication.

References

  1. 1.
    Hedegaard H., Minino A.M., Warner M. Drug Overdose Deaths in the United States, 1999-2017. NCHS Data Brief, no 329. Hyattsville, MD: National Center for Health Statistics; 2018.Google Scholar
  2. 2.
    Chou R, Korthuis PT, McCarty D, et al. Management of suspected opioid overdose with naloxone in out-of-hospital settings: a systematic review. Ann Intern Med. 2017;167(12):867-875.  https://doi.org/10.7326/M17-2224.CrossRefPubMedGoogle Scholar
  3. 3.
    Dunn KE, Barrett FS, Bigelow GE. Naloxone formulation for overdose reversal preference among patients receiving opioids for pain management. Addict Behav. 2018.  https://doi.org/10.1016/j.addbeh.2018.03.011.CrossRefGoogle Scholar
  4. 4.
    Pitt AL, Humphreys K, Brandeau ML. Modeling health benefits and harms of public policy responses to the US opioid epidemic. Am J Public Health. 2018;108(10):1394-1400.  https://doi.org/10.2105/AJPH.2018.304590.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Behar E, Bagnulo R, Coffin PO. Acceptability and feasibility of naloxone prescribing in primary care settings: a systematic review. Prev Med. 2018;114:79-87.  https://doi.org/10.1016/j.ypmed.2018.06.005.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Coffin PO, Behar E, Rowe C, et al. nonrandomized intervention study of naloxone coprescription for primary care patients receiving long-term opioid therapy for pain. Ann Intern Med. 2016;165(4):245-252.  https://doi.org/10.7326/M15-2771.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Office of the Surgeon General; US Department of Health and Human Services. Surgeon General’s Advisory on Naloxone and Opioid Overdose. http://www.surgeongeneral.gov. Accessed August 23, 2019.
  8. 8.
    Adams JM. Increasing naloxone awareness and use: the role of health care practitioners. JAMA. 2018;319(20):2073-2074.  https://doi.org/10.1001/jama.2018.4867.CrossRefPubMedGoogle Scholar
  9. 9.
    Dowell D, Haegerich TM, Chou R. CDC Guideline for Prescribing Opioids for Chronic Pain--United States, 2016. JAMA. 2016;315(15):1624-1645.  https://doi.org/10.1001/jama.2016.1464.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Park TW, Lin LA, Hosanagar A, Kogowski A, Paige K, Bohnert ASB. Understanding risk factors for opioid overdose in clinical populations to inform treatment and policy. J Addict Med. 2016;10(6):369-381.  https://doi.org/10.1097/ADM.0000000000000245.CrossRefPubMedGoogle Scholar
  11. 11.
    Bohnert ASB, Ilgen MA, Ignacio RV, McCarthy JF, Valenstein M, Blow FC. Risk of death from accidental overdose associated with psychiatric and substance use disorders. Am J Psychiatry. 2012;169(1):64-70.  https://doi.org/10.1176/appi.ajp.2011.10101476.CrossRefPubMedGoogle Scholar
  12. 12.
    Bohnert ASB, Valenstein M, Bair MJ, et al. Association between opioid prescribing patterns and opioid overdose-related deaths. JAMA. 2011;305(13):1315-1321.  https://doi.org/10.1001/jama.2011.370.CrossRefPubMedGoogle Scholar
  13. 13.
    Park TW, Saitz R, Ganoczy D, Ilgen MA, Bohnert ASB. Benzodiazepine prescribing patterns and deaths from drug overdose among US veterans receiving opioid analgesics: case-cohort study. BMJ. 2015;350:h2698.CrossRefGoogle Scholar
  14. 14.
    Paulozzi LJ. Prescription drug overdoses: a review. J Safety Res. 2012;43(4):283-289.  https://doi.org/10.1016/j.jsr.2012.08.009.CrossRefPubMedGoogle Scholar
  15. 15.
    Clark AK, Wilder CM, Winstanley EL. A systematic review of community opioid overdose prevention and naloxone distribution programs. J Addict Med. 2014;8(3):153-163.  https://doi.org/10.1097/ADM.0000000000000034.CrossRefPubMedGoogle Scholar
  16. 16.
    McDonald R, Strang J. Are take-home naloxone programmes effective? Systematic review utilizing application of the Bradford Hill criteria. Addiction. 2016;111(7):1177-1187.  https://doi.org/10.1111/add.13326.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
  18. 18.
    Guy GP, Zhang K, Bohm MK, et al. Vital signs: changes in opioid prescribing in the United States, 2006-2015. MMWR Morb Mortal Wkly Rep. 2017;66(26):697-704.  https://doi.org/10.15585/mmwr.mm6626a4.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Freeman PR, Hankosky ER, Lofwall MR, Talbert JC. The changing landscape of naloxone availability in the United States, 2011 - 2017. Drug Alcohol Depend. 2018;191:361-364.  https://doi.org/10.1016/j.drugalcdep.2018.07.017.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Centers for Disease Control and Prevention. Opioid Morphine Equivalent Conversion Factors. https://www.cms.gov/Medicare/Prescription-Drug-Coverage/PrescriptionDrugCovContra/Downloads/Opioid-Morphine-EQ-Conversion-Factors-March-2015.pdf. Accessed August 23, 2019.
  21. 21.
    Glanz JM, Narwaney KJ, Mueller SR, et al. Prediction model for two-year risk of opioid overdose among patients prescribed chronic opioid therapy. J Gen Intern Med. 2018.  https://doi.org/10.1007/s11606-017-4288-3.CrossRefGoogle Scholar
  22. 22.
    Oliva EM, Bowe T, Tavakoli S, et al. Development and applications of the Veterans Health Administration’s Stratification Tool for Opioid Risk Mitigation (STORM) to improve opioid safety and prevent overdose and suicide. Psychol Serv. 2017;14(1):34-49.  https://doi.org/10.1037/ser0000099.CrossRefPubMedGoogle Scholar
  23. 23.
    Jones CM, Lurie PG, Compton WM. Increase in naloxone prescriptions dispensed in US retail pharmacies since 2013. Am J Public Health. 2016;106(4):689-690.  https://doi.org/10.2105/AJPH.2016.303062.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Behar E, Rowe C, Santos G-M, et al. Acceptability of naloxone co-prescription among primary care providers treating patients on long-term opioid therapy for pain. J Gen Intern Med. 2017;32(3):291-295.  https://doi.org/10.1007/s11606-016-3911-z.CrossRefPubMedGoogle Scholar
  25. 25.
    Kariisa M, Scholl L, Wilson N, Seth P, Hoots B. Drug overdose deaths involving cocaine and psychostimulants with abuse potential - United States, 2003-2017. MMWR Morb Mortal Wkly Rep. 2019;68(17):388-395.  https://doi.org/10.15585/mmwr.mm6817a3.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Olfson M, Wall M, Wang S, Crystal S, Blanco C. Risks of fatal opioid overdose during the first year following nonfatal overdose. Drug Alcohol Depend. 2018;190:112-119.  https://doi.org/10.1016/j.drugalcdep.2018.06.004.CrossRefPubMedGoogle Scholar
  27. 27.
    Kirane H, Ketteringham M, Bereket S, et al. Awareness and attitudes toward intranasal naloxone rescue for opioid overdose prevention. J Subst Abuse Treat. 2016;69:44-49.  https://doi.org/10.1016/j.jsat.2016.07.005.CrossRefPubMedGoogle Scholar
  28. 28.
    Binswanger IA, Koester S, Mueller SR, Gardner EM, Goddard K, Glanz JM. Overdose education and naloxone for patients prescribed opioids in primary care: a qualitative study of primary care staff. J Gen Intern Med. 2015;30(12):1837-1844.  https://doi.org/10.1007/s11606-015-3394-3.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Winograd RP, Davis CS, Niculete M, Oliva E, Martielli RP. Medical providers’ knowledge and concerns about opioid overdose education and take-home naloxone rescue kits within Veterans Affairs health care medical treatment settings. Subst Abus. 2017;38(2):135-140.  https://doi.org/10.1080/08897077.2017.1303424.CrossRefPubMedGoogle Scholar
  30. 30.
    Ashrafioun L, Gamble S, Herrmann M, Baciewicz G. Evaluation of knowledge and confidence following opioid overdose prevention training: A comparison of types of training participants and naloxone administration methods. Subst Abus. 2016;37(1):76-81.  https://doi.org/10.1080/08897077.2015.1110550.CrossRefPubMedGoogle Scholar
  31. 31.
    Kerensky T, Walley AY. Opioid overdose prevention and naloxone rescue kits: what we know and what we don’t know. Addict Sci Clin Pract. 2017;12.  https://doi.org/10.1186/s13722-016-0068-3.
  32. 32.
    PDAPS - Naloxone Overdose Prevention Laws. http://pdaps.org/datasets/laws-regulating-administration-of-naloxone-1501695139. Accessed August 23, 2019.
  33. 33.
    Gertner AK, Domino ME, Davis CS. Do naloxone access laws increase outpatient naloxone prescriptions? Evidence from Medicaid. Drug Alcohol Depend. 2018;190:37-41.  https://doi.org/10.1016/j.drugalcdep.2018.05.014.CrossRefPubMedGoogle Scholar
  34. 34.
    Guadamuz JS, Alexander GC, Chaudhri T, Trotzky-Sirr R, Qato DM. Availability and Cost of Naloxone Nasal Spray at Pharmacies in Philadelphia, Pennsylvania, 2017. JAMA Netw Open. 2019;2(6).  https://doi.org/10.1001/jamanetworkopen.2019.5388.CrossRefGoogle Scholar
  35. 35.
    Puzantian T, Gasper JJ. Provision of naloxone without a prescription by california pharmacists 2 years after legislation implementation. JAMA. 2018;320(18):1933-1934.  https://doi.org/10.1001/jama.2018.12291.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Sohn M, Talbert JC, Huang Z, Lofwall MR, Freeman PR. Association of naloxone coprescription laws with naloxone prescription dispensing in the United States. JAMA Netw Open. 2019;2(6):e196215.  https://doi.org/10.1001/jamanetworkopen.2019.6215.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Larochelle MR, Liebschutz JM, Zhang F, Ross-Degnan D, Wharam JF. Opioid prescribing after nonfatal overdose and association with repeated overdose: a cohort study. Ann Intern Med. 2016;164(1):1-9.  https://doi.org/10.7326/M15-0038.CrossRefPubMedGoogle Scholar
  38. 38.
    Wollschlaeger BA, Willson TM, Montejano LB, Ronquest NA, Nadipelli VR. Characteristics and treatment patterns of US commercially insured and Medicaid patients with opioid dependence or abuse. J Opioid Manag. 2017;13(4):207-220.  https://doi.org/10.5055/jom.2017.0389.CrossRefPubMedGoogle Scholar
  39. 39.
    Ali MM, Tehrani AB, Mutter R, et al. Factors associated with potentially problematic opioid prescriptions among individuals with private insurance and medicaid. Addict Behav. 2019;98:106016.  https://doi.org/10.1016/j.addbeh.2019.06.005.CrossRefPubMedGoogle Scholar
  40. 40.
    Murphy SM, Morgan JR, Jeng PJ, Schackman BR. Will converting naloxone to over-the-counter status increase pharmacy sales? Health Serv Res. 2019.  https://doi.org/10.1111/1475-6773.13125.CrossRefGoogle Scholar

Copyright information

© Society of General Internal Medicine (This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply) 2019

Authors and Affiliations

  • Lewei (Allison) Lin
    • 1
    • 2
    • 3
    Email author
  • Chad M. Brummett
    • 3
    • 4
  • Jennifer F. Waljee
    • 3
    • 5
  • Michael J. Englesbe
    • 3
    • 5
  • Vidhya Gunaseelan
    • 3
    • 5
  • Amy S. B. Bohnert
    • 1
    • 2
    • 3
  1. 1.Department of Psychiatry University of MichiganAnn ArborUSA
  2. 2.VA Center for Clinical Management Research (CCMR)VA Ann Arbor Healthcare SystemAnn ArborUSA
  3. 3.Michigan Opioid Prescribing Engagement NetworkAnn ArborUSA
  4. 4.Department of AnesthesiologyUniversity of MichiganAnn ArborUSA
  5. 5.Department of SurgeryUniversity of MichiganAnn ArborUSA

Personalised recommendations